Proteomics approaches to research protein-DNA interactions in human diseases

Introduction

Protein-DNA interactions are fundamental to the regulation of various cellular functions, including gene expression, DNA replication, and repair. These interactions are dynamic and critical for maintaining cellular homeostasis, and their dysregulation has been implicated in numerous human diseases, including cancer, neurodegenerative disorders, and autoimmune diseases [1] . Proteomics, the large-scale research of proteins, offers a comprehensive approach to investigating these interactions. By utilizing high-throughput techniques, proteomics can identify key proteins that interact with DNA and explore their role in disease mechanisms. Chromatin immunoprecipitation (ChIP)-sequencing is one of the most widely used proteomic methods for researching protein-DNA interactions. This technique allows for the identification of DNA regions bound by specific proteins, providing insights into the transcriptional regulation and epigenetic modifications associated with disease [2] . Another valuable approach is affinity purification-mass spectrometry (AP-MS), which enables the identification of protein complexes involved in DNA interactions [3] . These techniques, when combined with next-generation sequencing technologies, provide a powerful tool to map the protein-DNA interactome and uncover the molecular mechanisms underlying disease pathogenesis. In the context of cancer, proteomic studies have revealed that specific protein-DNA interactions play a key role in tumorigenesis. For example, mutations in DNA repair proteins or alterations in transcription factors can lead to the activation of oncogenic pathways and resistance to chemotherapy [4] . Similarly, in neurodegenerative diseases, protein-DNA interactions are involved in the regulation of genes associated with neuronal survival and synaptic plasticity [5] . Understanding these interactions in the context of disease is crucial for identifying new biomarkers and therapeutic targets. Despite the promise of proteomics in researching protein-DNA interactions, challenges remain in overcoming issues such as sample complexity, the need for precise identification of low-abundance proteins, and the interpretation of vast data sets [6] . The integration of proteomics with other omics approaches, such as genomics and transcriptomics, holds the potential to provide a more comprehensive understanding of protein-DNA interactions in human diseases [7] . By addressing these challenges, proteomics will continue to play a pivotal role in advancing our knowledge of disease mechanisms and therapeutic development.

Materials and Methods Materials

In this research, human cell lines representing different disease models were used for proteomic analysis of protein-DNA interactions. Specifically, breast cancer (MCF-7), neurodegenerative disorder (SH-SY5Y), and autoimmune disorder (Jurkat T cells) cell lines were selected to investigate the role of protein-DNA interactions in disease progression [1] . Protein extracts were prepared from these cell lines using a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, and protease inhibitors. DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen, USA) according to the manufacturer's protocol. Antibodies against specific transcription factors (e.g., p53, NF-κB, and STAT3) were purchased from Cell Signaling Technology (USA), and secondary antibodies conjugated with horseradish peroxidase (HRP) were used for immunoblotting. Mass spectrometry analysis was performed using a Thermo Fisher Scientific Orbitrap Fusion mass spectrometer coupled with an Easy-nLC 1200 system (Thermo Fisher Scientific, USA) [2, 3] .

Methods: To research protein-DNA interactions, chromatin immunoprecipitation followed by sequencing (ChIP-Seq) was employed as the primary technique. Briefly, the cells were crosslinked with formaldehyde, followed by chromatin shearing using a Bio ruptor sonicator. Immunoprecipitation was performed using antibodies against transcription factors and histone modifications associated with active gene expression. After ChIP, DNA was purified and sequenced using the Illumina HiSeq platform. Additionally, affinity purification-mass spectrometry (AP-MS) was used to identify protein complexes associated with DNA binding [4] . Data obtained from ChIP-Seq and AP-MS were analyzed using the MaxQuant software to identify and quantify the proteins involved in protein-DNA interactions [5] . Statistical analysis was performed using RStudio software for differential expression analysis and network analysis of protein-DNA interactions [6] . The statistical significance of the interactions was determined using a t-test and ANOVA where applicable. were obtained in the neurodegenerative and autoimmune models, where STAT3 was upregulated, indicating its role in cell survival and inflammation [7] . Network analysis revealed significant protein-DNA interaction networks involving these transcription factors. Statistical tools such as ANOVA and regression analysis were applied to the data, showing that the protein-DNA interactions are strongly associated with disease progression and response to therapeutic agents. These findings suggest that therapeutic targeting of these protein-DNA interactions could offer new insights into the management of cancer, neurodegenerative diseases, and autoimmune disorders.

Results

Discussion

The findings of this research underscore the importance of protein-DNA interactions in the development of human diseases. Through the application of ChIP-Seq and AP-MS, we identified key proteins such as p53, NF-κB, and STAT3 that are involved in gene regulation and disease progression. The upregulation of p53 and STAT3 in the breast cancer cell model (MCF-7) suggests that these proteins play pivotal roles in cell survival and tumorigenesis, while the downregulation of NF-κB points to its potential role in inflammatory responses and immune modulation in cancer.

In neurodegenerative diseases, the role of STAT3 in neuronal survival was consistent with previous studies, confirming its involvement in neuroprotection [5] . Similarly, in autoimmune disorders, altered protein-DNA interactions could serve as therapeutic targets, as seen with the dysregulation of immune response pathways. The integration of proteomics with genomics and transcriptomics in this research provides a comprehensive view of the molecular mechanisms involved in protein-DNA interactions. However, there are limitations in the current methodology, such as the complexity of the data analysis and the potential for false positives in protein identification. The research also highlights the need for more refined proteomic techniques to research low-abundance proteins and their interactions. Future research should focus on the validation of these findings in clinical samples and explore the potential for developing small molecules or antibodies that can disrupt specific protein-DNA interactions as therapeutic agents.

Conclusion

This research emphasizes the significant role of protein-DNA interactions in the pathogenesis of various human diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Through the use of advanced proteomics techniques, including ChIP-Seq and AP-MS, key transcription factors such as p53, NF-κB, and STAT3 have been identified as crucial players in disease progression. The findings not only enhance our understanding of the molecular mechanisms underlying these diseases but also provide potential therapeutic targets for future interventions. By targeting protein-DNA interactions, novel strategies could be developed to prevent or treat diseases characterized by dysregulated gene expression. Additionally, integrating proteomics with other omics technologies will be essential for a more comprehensive understanding of disease mechanisms and for the development of personalized therapeutic approaches. Practical recommendations from this research include further validation of the identified protein-DNA interactions in clinical settings, particularly in patient samples, to assess their relevance as biomarkers. Moreover, the development of drugs targeting these interactions, such as small molecules or antibodies, could significantly enhance treatment options for cancers, neurodegenerative diseases, and autoimmune disorders. Collaboration between researchers, clinicians, and pharmaceutical companies will be key to translating these findings into clinical practice. Additionally, the incorporation of advanced computational tools for data analysis and prediction will be critical in identifying novel therapeutic targets and optimizing treatment strategies. It is also important to continue improving the sensitivity and specificity of proteomics techniques to ensure that subtle changes in protein-DNA interactions can be detected early in disease progression.

Acknowledgement

Acknowledgements Funding Sources Other AcknowledgementsThe authors also wish to express their gratitude to Prof. Anna Rossi at the Institute for Molecular Biology, Milan, Italy, for her technical expertise and support throughout the research. Additionally, the authors appreciate the feedback provided by the peer reviewers, which greatly enhanced the quality of this manuscript.

References

1. Smith J, Brown L, Wong K, et al. Proteomics and its applications in human diseases. J Proteomics. 2021;220:103505.
2. Zhang X, Li Y, Wang X. Chromatin immunoprecipitation followed by sequencing: current applications in disease research. Front Genet. 2020;11:711.
3. Chen H, Zhou Y, Wang X, et al. Affinity purificationmass spectrometry for studying protein-DNA interactions in disease models. Methods Mol Biol. 2021;2219:145-160.
4. Anderson P, McAllister D, Nguyen K. Role of p53 in breast cancer: proteomics insights into transcription factor binding. Breast Cancer Res. 2020;22(1):85.
5. Davidson H, Garcia C, Hudson S, et al. Transcriptional dysregulation of NF-κB in neurodegenerative diseases. Brain Res. 2022;1780:97-106.
6. Clarke M, Fisher J, Saito M, et al. STAT3 signaling in autoimmune disorders: new insights from proteomic analyses. Autoimmune Rev. 2021;20(1):102478.
7. Edwards R, Tran J, Kahn D, et al. Protein-DNA interactions in cancer: a systematic review of proteomics applications. Cancer Genomics Proteomics. 2019;16(4):221-233.
8. Reilly S, Taylor G, Norman E, et al. Mass spectrometry-based proteomics in the study of proteinDNA complexes. J Mol Biol. 2020;432(18):5795-5808.
9. Morris C, Wilson H, Baker L, et al. Advances in proteomics techniques for protein-DNA interaction studies. Trends Biotechnol. 2021;39(3):302-315.
10. Thompson J, Zhang T, Nelson D, et al. The role of protein-DNA interactions in tumorigenesis: implications for drug development. Cancer Res. 2020;80(10):2143-2155.
11. Wu Z, Tan H, Zhang S, et al. Investigating transcription factors as therapeutic targets in cancer: a proteomic approach. J Cancer. 2020;11(12):3565-3573.
12. Lin Z, Yang X, Yu X, et al. Proteomics approaches for identifying biomarkers in neurodegenerative diseases. J Neurochem. 2021;158(4):635-646.
13. Zhao Y, Liu J, Wang R, et al. Exploring protein-DNA interactions in autoimmune diseases: proteomics as a tool. Autoimmunity. 2020;53(8):497-510.
14. Hart D, Miller S, Taylor M, et al. Integrating multiomics in understanding protein-DNA interactions: implications for therapeutic strategies. Cell Mol Life Sci. 2021;78(11):5421-5435.